The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of the anti-programmed death ligand-1 antibody durvalumab (D; MEDI4736) in combination with PARP inhibitor, olaparib (O), in metastatic castration-resistant prostate cancer (mCRPC).
 
Fatima Karzai
No Relationships to Disclose
 
Ravi Amrit Madan
Speakers' Bureau - Boehringer Ingelheim (I); Janssen (I); Pfizer (I)
 
Helen Owens
No Relationships to Disclose
 
Amy Hankin
No Relationships to Disclose
 
Anna Couvillon
No Relationships to Disclose
 
Nicole D. Houston
No Relationships to Disclose
 
Farhad Fakhrejahani
No Relationships to Disclose
 
Marijo Bilusic
Consulting or Advisory Role - Astellas Pharma; Bayer; Dendreon; Genomic Health
Speakers' Bureau - Dendreon
Research Funding - Advaxis (Inst); Ambry Genetics (Inst); Bavarian Nordic (Inst); Johnson & Johnson (Inst); Sotio (Inst)
 
Marc Robert Theoret
No Relationships to Disclose
 
Lisa M Cordes
No Relationships to Disclose
 
Jane B. Trepel
No Relationships to Disclose
 
Daniel C. Edelman
No Relationships to Disclose
 
Paul S. Meltzer
No Relationships to Disclose
 
James L. Gulley
Consulting or Advisory Role - TRM Oncology
 
William L. Dahut
No Relationships to Disclose
 
Jung-min Lee
No Relationships to Disclose